Discover

APGE
Apogee Therapeutics, Inc.
132.77
2 x 95.56
4 x 133.00
bid
ask
+
0.04
0.03%
3 @ 04:00 PM
132.65 -0.13 (0.09%)
Ytd75.90%
1y199.98%
132.69
day range
132.85
34.34
52 week range
133.16
Open132.75Prev Close132.73Low132.69High132.85Mkt Cap9.98B
Vol3.48MAvg Vol2.40MEPS-4.33P/EN/AForward P/E-25.59
Beta0.62Short Ratio9.81Inst. Own131.59%DividendN/ADiv YieldN/A
Ex Div DateN/AEarning08-1050-d Avg91.77200-d Avg73.181yr Est130.53

APGE News

Shareholder Alert: Ademi LLP investigates whether Apogee Therapeutics is obtaining a Fair Price for Public Shareholders
globenewswire.com
Shareholder Alert: Ademi LLP investigates whether Apogee Therapeutics is obtaining a Fair Price for

MILWAUKEE, July 02, 2026 (GLOBE NEWSWIRE) -- Ademi LLP is investigating Apogee (NASDAQ: APGE) for po

This Pharmaceutical Giant Just Poured $11 Billion on an Acquisition. Time to Buy?
fool.com
This Pharmaceutical Giant Just Poured $11 Billion on an Acquisition. Time to Buy?

AbbVie knows how to plan ahead.

Biotech Bigwigs ABBV, JNJ, BIIB & LLY Hit New 52-Week Highs
zacks.com
Biotech Bigwigs ABBV, JNJ, BIIB & LLY Hit New 52-Week Highs

LLY, ABBV, BIIB and JNJ hit new 52-week highs as biotech rallies, with company-specific pipeline, ap

Deal Dispatch: Penske Buys Vox Media's Digital Brands, AbbVie Acquires Apogee Therapeutics For $10.9 Billion, Camp Mystic Bankruptcy
benzinga.com
Deal Dispatch: Penske Buys Vox Media's Digital Brands, AbbVie Acquires Apogee Therapeutics For $10.9

Major M&A deals this week include: Adobe buys Topaz Labs, Rise Baking Company purchases Jimmy&#3

Are TECH, APGE, BOLD, REFI Obtaining Fair Deals for their Shareholders?
gurufocus.com
Are TECH, APGE, BOLD, REFI Obtaining Fair Deals for their Shareholders?

Are TECH, APGE, BOLD, REFI Obtaining Fair Deals for their Shareholders? PR Newswire NEW YORK, June 2

Biotech ETF Index Surges 10% After Rebalance
etftrends.com
Biotech ETF Index Surges 10% After Rebalance

After a sweeping semi-annual rebalance, the biotech index underlying the ALPS Medical Breakthroughs

Is AbbVie a Buy After Its Purchase of Apogee?
fool.com
Is AbbVie a Buy After Its Purchase of Apogee?

The pharmaceutical company gains a prospective blockbuster with the deal, but is it worth $10.9 bill

benzinga.com
Stifel Downgrades Apogee Therapeutics to Hold, Raises Price Target to $135

Stifel analyst Akash Tewari downgrades Apogee Therapeutics (NASDAQ:APGE) from Buy to Hold and rai

Okta To Rally More Than 18%? Here Are 10 Top Analyst Forecasts For Wednesday
benzinga.com
Okta To Rally More Than 18%? Here Are 10 Top Analyst Forecasts For Wednesday

Top Wall Street analysts changed their outlook on top names. See all analyst rating changes, includi

This Principal Financial Group Analyst Turns Bearish; Here Are Top 5 Downgrades For Wednesday
benzinga.com
This Principal Financial Group Analyst Turns Bearish; Here Are Top 5 Downgrades For Wednesday

Top Wall Street analysts changed outlook on top names. View all changes on analyst ratings page. See

benzinga.com
Mizuho Downgrades Apogee Therapeutics to Neutral, Raises Price Target to $135

Mizuho analyst Joseph Catanzaro downgrades Apogee Therapeutics (NASDAQ:APGE) from Outperform to N

benzinga.com
Deutsche Bank Downgrades Apogee Therapeutics to Hold, Raises Price Target to $135

Deutsche Bank analyst David Hoang downgrades Apogee Therapeutics (NASDAQ:APGE) from Buy to Hold a

AbbVie’s Costly Apogee Acquisition Has Long-Term Upside: Analyst
benzinga.com
AbbVie’s Costly Apogee Acquisition Has Long-Term Upside: Analyst

AbbVie will acquire Apogee Therapeutics for $10.9 billion, with analyst citing long-term immunology

This IBM Analyst Turns Bullish; Here Are Top 3 Upgrades For Tuesday
benzinga.com
This IBM Analyst Turns Bullish; Here Are Top 3 Upgrades For Tuesday

Top Wall Street analysts changed outlook on top names. Piper Sandler upgraded SNPS, JP Morgan upgrad

benzinga.com
Citigroup Downgrades Apogee Therapeutics to Neutral, Raises Price Target to $135

Citigroup analyst Geoff Meacham downgrades Apogee Therapeutics (NASDAQ:APGE) from Buy to Neutral

benzinga.com
RBC Capital Maintains Sector Perform on Apogee Therapeutics, Raises Price Target to $135

RBC Capital analyst Brian Abrahams maintains Apogee Therapeutics (NASDAQ:APGE) with a Sector Perf

This Insulet Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday
benzinga.com
This Insulet Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday

Wall Street analysts changed outlook on top names, including MCRB, SAFX. See analyst ratings page fo

benzinga.com
UBS Downgrades Apogee Therapeutics to Neutral, Raises Price Target to $135.11

UBS analyst Michael Yee downgrades Apogee Therapeutics (NASDAQ:APGE) from Buy to Neutral and rais

This Zions Bancorp Analyst Is No Longer Bullish; Here Are Top 3 Downgrades For Tuesday
benzinga.com
This Zions Bancorp Analyst Is No Longer Bullish; Here Are Top 3 Downgrades For Tuesday

Wall Street analysts changed ratings for PRIM, ZION, and APGE. Check out analysts' views on thes

benzinga.com
Wedbush Downgrades Apogee Therapeutics to Neutral, Maintains Price Target to $135

Wedbush analyst David Nierengarten downgrades Apogee Therapeutics (NASDAQ:APGE) from Outperform t

benzinga.com
12 Health Care Stocks Moving In Monday's Intraday Session

Gainers Tenon Medical (NASDAQ:TNON) stock moved upwards by 79.6% to $0.63 during Monday's regul

Apogee Therapeutics, Definium Therapeutics, Baldwin Insurance And Other Big Stocks Moving Higher On Monday
benzinga.com
Apogee Therapeutics, Definium Therapeutics, Baldwin Insurance And Other Big Stocks Moving Higher On

U.S. stocks up with Dow Jones gaining 200+ points. AbbVie Inc. announced acquisition of Apogee Thera

Crude Oil Falls Over 2%; Getty Images Shares Spike Higher
benzinga.com
Crude Oil Falls Over 2%; Getty Images Shares Spike Higher

U.S. stocks traded mixed midway through trading, with the Nasdaq Composite falling more than 300 poi

AbbVie Expands Immunology Footprint With Apogee $11 Billion Acquisition
benzinga.com
AbbVie Expands Immunology Footprint With Apogee $11 Billion Acquisition

AbbVie will acquire Apogee for $10.9 billion, adding late-stage immunology and asthma assets to its

benzinga.com
12 Health Care Stocks Moving In Monday's Pre-Market Session

Gainers Tenon Medical (NASDAQ:TNON) shares increased by 115.8% to $0.76 during Monday's pre-mar

benzinga.com
AbbVie To Acquire Apogee And Its Diverse Pipeline Of Multiple Clinical-Stage Candidates In Developme

Proposed acquisition adds a diverse pipeline of assets focused on elevating the standard of care for

Why Sagtec Global Shares Are Trading Higher By Around 76%; Here Are 20 Stocks Moving Premarket
benzinga.com
Why Sagtec Global Shares Are Trading Higher By Around 76%; Here Are 20 Stocks Moving Premarket

SAGTEC GLOBAL (NASDAQ: SAGT) gained 75.6% in pre-market trading after projecting 35% revenue growth

benzinga.com
Reported Friday, 'AbbVie closes in on nearly $11bn deal for biotech Apogee Therapeutics' - FT

https://www.ft.com/content/cb5e94aa-1687-47fe-b55a-82e273e8b1bd?syn-25a6b1a6=1 

benzinga.com
RBC Capital Maintains Sector Perform on Apogee Therapeutics, Raises Price Target to $97

RBC Capital analyst Brian Abrahams maintains Apogee Therapeutics (NASDAQ:APGE) with a Sector Perf

benzinga.com
Truist Securities Maintains Hold on Apogee Therapeutics, Lowers Price Target to $81

Truist Securities analyst Danielle Brill maintains Apogee Therapeutics (NASDAQ:APGE) with a Hold

benzinga.com
BTIG Reiterates Buy on Apogee Therapeutics, Maintains $137 Price Target

BTIG analyst Julian Harrison reiterates Apogee Therapeutics (NASDAQ:APGE) with a Buy and maintain

Apogee Stock Slides After Blackstone Financing Deal And Positive Drug Data
benzinga.com
Apogee Stock Slides After Blackstone Financing Deal And Positive Drug Data

Apogee shares fell after announcing a $1.3 billion Blackstone financing deal alongside positive Phas

benzinga.com
Wedbush Maintains Outperform on Apogee Therapeutics, Raises Price Target to $135

Wedbush analyst David Nierengarten maintains Apogee Therapeutics (NASDAQ:APGE) with a Outperform

benzinga.com
Apogee Therapeutics Says Phase 2 APEX Trial Of Zumilokibart Met Primary And Secondary Endpoints; 65.

APEX Part B met all primary and secondary endpoints with high statistical significance; mid-dose zum

benzinga.com
Apogee Therapeutics Enters Strategic Financing Collaboration With Blackstone For Up To $1.3B In Non-

Up to $1.3 billion in flexible, non-dilutive capital, including up to $800 million of synthetic roya

benzinga.com
Apogee Therapeutics Q1 EPS $(1.06) Beats $(1.08) Estimate

Apogee Therapeutics (NASDAQ:APGE) reported quarterly losses of $(1.06) per share which beat the anal

benzinga.com
Rothschild & Co Initiates Coverage On Apogee Therapeutics with Buy Rating, Announces Price Target of

Rothschild & Co analyst Qize Ding initiates coverage on Apogee Therapeutics (NASDAQ:APGE) wit

benzinga.com
Mizuho Maintains Outperform on Apogee Therapeutics, Raises Price Target to $110

Mizuho analyst Joseph Catanzaro maintains Apogee Therapeutics (NASDAQ:APGE) with a Outperform and

benzinga.com
Citigroup Maintains Buy on Apogee Therapeutics, Raises Price Target to $125

Citigroup analyst Geoff Meacham maintains Apogee Therapeutics (NASDAQ:APGE) with a Buy and raises

benzinga.com
Canaccord Genuity Maintains Buy on Apogee Therapeutics, Raises Price Target to $130

Canaccord Genuity analyst Edward Nash maintains Apogee Therapeutics (NASDAQ:APGE) with a Buy and

benzinga.com
Guggenheim Maintains Buy on Apogee Therapeutics, Raises Price Target to $160

Guggenheim analyst Seamus Fernandez maintains Apogee Therapeutics (NASDAQ:APGE) with a Buy and ra

benzinga.com
Apogee Announces $300M Stock Offering

In addition, Apogee expects to grant the underwriters a 30-day option to purchase up to an additiona

Crude Oil Falls Sharply; Dell Shares Spike Higher
benzinga.com
Crude Oil Falls Sharply; Dell Shares Spike Higher

Dow up 2.45%, Nasdaq up 2.46%, S&P 500 up 2.19%. Consumer discretionary shares up 3.6%, energy s

benzinga.com
BTIG Reiterates Buy on Apogee Therapeutics, Maintains $137 Price Target

BTIG analyst Julian Harrison reiterates Apogee Therapeutics (NASDAQ:APGE) with a Buy and maintain

Apogee Therapeutics, Tower Semiconductor, Norwegian Cruise Line And Other Big Stocks Moving Higher On Thursday
benzinga.com
Apogee Therapeutics, Tower Semiconductor, Norwegian Cruise Line And Other Big Stocks Moving Higher O

Stocks fall, Nasdaq drops 200 points. Apogee Therapeutics (APGE) rises 19.4% on positive trial data.

Dow Jumps Over 800 Points; Chicago Fed National Activity Index Declines In February
benzinga.com
Dow Jumps Over 800 Points; Chicago Fed National Activity Index Declines In February

Dow Jones rises over 800 points on Monday as U.S. stocks trade higher. NASDAQ and S&P 500 also s

Apogee Therapeutics Stock Rallies On Encouraging Eczema Drug Data Readout
benzinga.com
Apogee Therapeutics Stock Rallies On Encouraging Eczema Drug Data Readout

Apogee Therapeutics stock jumps on 52-week eczema data; durable response supports Phase 3 plans late

12 Health Care Stocks Moving In Monday's Pre-Market Session
benzinga.com
12 Health Care Stocks Moving In Monday's Pre-Market Session

benzinga.com
Apogee Therapeutics Reports 52-Week Maintenance Data From Part A Of Phase 2 APEX Clinical Trial Of Z

APEX Part A data demonstrated durable maintenance of response at 52-weeks for every 3- and 6-months

This Rubrik Analyst Begins Coverage On A Bullish Note; Here Are Top 4 Initiations For Friday
benzinga.com
This Rubrik Analyst Begins Coverage On A Bullish Note; Here Are Top 4 Initiations For Friday

Wall Street analysts changed ratings on top stocks. For insights on changes, see analyst ratings pag